of Non-Compliance with 37 C.F.R. §1.192(c) mailed from the Patent Office on September 24, 1998.

In the Claims

Please cancel claims 103-107, 110-113, 118, 119, and 124-127.

Please amend the claims as follows (For the Examiner's convenience, all of the pending claims as amended are set forth in Appendix A):

114. (Amended) The method as in any one of claims 108-109 [103-113] wherein the peptide is modified by at least one amino acid substitution, addition or deletion, said peptide comprising a T cell epitope recognized by a T cell receptor specific for the protein allergen.

115. (Amended) The method as in any one of claims 108-109 [105-109], wherein the peptide is purified to at least about 90% purity.

120. (Amended) The method as in any one of claims 108-109 [103-113], wherein the peptide is at least about 12 amino acid residues in length.

121. (Amended) The method as in any one of claims 108-109 [103-113], wherein the at least one peptide comprises at least two peptides.

122. (Amended) The method as any one of claims 108-109 [103-113], wherein the protein allergen is selected from the group consisting of: a protein allergen of the genus *Dermatophagoides*; a protein allergen of the genus *Felis*; a protein allergen of the genus *Ambrosia*; a protein allergen of the genus *Lolium*; a protein allergen of the genus *Cryptomeria*; a protein allergen of the genus *Alternaria*; a protein allergen of the genus *Alder*; a protein allergen of the genus *Betula*; a protein allergen of the genus *Quercus*; a protein allergen of the genus *Olea*; a protein allergen of the genus *Artemisia*; a protein allergen of the genus *Plantago*; a protein allergen of the genus *Parietaria*; a protein allergen of the genus *Canine*; a protein allergen of the genus *Blattella*; a protein allergen of the genus *Apis*; a protein allergen of the genus *Cupressus*; a protein allergen of the genus *Juniperus*; a protein allergen of the genus *Thuya*; a protein allergen of the genus

Chamaecyparis; a protein allergen of the genus *Periplaneta*; a protein allergen of the genus *Agropyron*; a protein allergen of the genus *Secale*; a protein allergen of the genus *Triticum*; a protein allergen of the genus *Dactylis*; a protein allergen of the genus *Festuca*; a protein allergen of the genus *Poa*; a protein allergen of the genus *Avena*; a protein allergen of the genus *Holcus*; a protein allergen of the genus *Anthoxanthum*; a protein allergen of the genus *Arrhenatherum*; a protein allergen of the genus *Agrostis*; a protein allergen of the genus *Phleum*; a protein allergen of the genus *Phalaris*; a protein allergen of the genus *Paspalum*; and a protein allergen of the genus *Sorghum*.

128. (Amended) The method as in any one of claims 108-109 [103-113], wherein the composition further comprises a pharmaceutically acceptable carrier.

130. (Amended) The method as in any one of 108-109 [103-113], wherein the composition is soluble in an aqueous solution at a physiologically acceptable pH.

131. (Amended) The method as in any one of claims 108-109 [103-113], wherein said administering comprises a route of administration selected from the group consisting of oral, intravenous, sublingual, transdermal, inhalation, subcutaneous and rectal.

133. (Amended) The method as in any one of claims 108-109 [103-113], wherein said composition is administered without adjuvant [in non-immunogenic form].

134. (Amended) The method as in any one of claims 108-109 [103-113] comprising administering an initial treatment of three to six dosages of said composition over a period of no more than 6 weeks.

136. (Amended) The method as in any one of 108-109 [103-113], wherein said initial treatment comprises increasing the dosage with each subsequent additional dosage of said composition.

137. (Amended) The method as in any one of claims 108-109 [103-113], wherein said initial treatment comprises decreasing the dosage with each subsequent additional dosage of said composition.